Patents by Inventor Richard A. Lerner

Richard A. Lerner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200400676
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: August 3, 2020
    Publication date: December 24, 2020
    Applicants: OPKO Pharmaceuticals, LLC, The Scripps Research Institute, Shemyakin-Ovchinnikov institute of Bioorganic Chemistry, Russian Academy of Sciences, PJSC Pharmsynthez
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • Publication number: 20200363420
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Applicants: OPKO Pharmaceuticals, LLC, The Scripps Research Institute, Shemyakin-Ovchinnikov institute of Bioorganic Chemistry, Russian Academy of Sciences, PJSC Pharmsynthez
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • Publication number: 20200271657
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 27, 2020
    Applicants: OPKO Pharmaceuticals, LLC, The Scripps Research Institute, Bioorganic Chemistry, Russian Academy of Sciences, PJSC Pharmsynthez
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • Patent number: 10745456
    Abstract: The invention provides combinatorial peptide or polypeptide libraries that can become membrane tethered once expressed in cells. The invention additionally provides methods for selecting peptide modulators (e.g., agonists) of GPCRs from the combinatorial libraries of the invention. The invention also provides novel GPCR polypeptide modulators, e.g., biased polypeptide agonists of the glucagon-like peptide 1 receptor (GLP-1R). The invention further provides methods of promoting insulin sensitivity, lowering blood glucose, and reducing body weight as well as methods for treating various diseases such as diabetes and obesity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 18, 2020
    Assignee: The Scripps Research Institute
    Inventors: Richard A. Lerner, Hongkai Zhang, Patricia McDonald, Jia Xie, Emmanuel Sturchler, Philip Dawson
  • Publication number: 20200190151
    Abstract: The invention provides variant venom peptides and polypeptides that specifically block potassium voltage gated ion channel Kv1.3. The invention also provides methods of inhibiting Kv1.3 channel activity, methods for treating disorders that are associated with undesired or aberrant Kv1.3 channel activity, methods for detecting Kv1.3 expression in target cells such as lymphocytes, and methods for diagnosing diseases or disorders that are associated with aberrant Kv1.3 overexpression.
    Type: Application
    Filed: May 11, 2017
    Publication date: June 18, 2020
    Inventors: Richard A. Lerner, Hongkai Zhang
  • Patent number: 10655124
    Abstract: The invention provides methods for identifying binding partners (e.g., peptide ligands) that binds to a target protein (e.g., a cellular receptor). The methods entail co-localized expression of the target protein and candidate binding partners, and selection of binding partners based on their proximity in the plasma membrane.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: May 19, 2020
    Assignee: The Scripps Research Institute
    Inventors: Richard A. Lerner, Hongkai Zhang, Jia Xie
  • Publication number: 20200140851
    Abstract: The Invention provides in vivo selection methods for identifying modulating agents (e.g., antibodies or polypeptides) that promote cellular differentiation and migration. The methods utilize a combinatorial agent library (e.g., antibodies expressed via lentiviral vectors) that are expressed in a population of to-be modulated cells (e.g., stem cells), which are then introduced into, the body of a non-hum an animal (e.g., mouse). This is followed by examining an organ or tissue of interest (e.g., brain) of the manipulated animal for the presence of a modulating agent and/or a specific phenotype. The; invention also provides specific antibody agent, that can induce differentiation of stem cells into microglia and migration into the brain. Further provided in the invention are therapeutic applications of the microglia-inducing antibodies.
    Type: Application
    Filed: August 18, 2017
    Publication date: May 7, 2020
    Inventors: Kyung Ho Han, Richard A. Lerner
  • Patent number: 10494438
    Abstract: The invention provides methods for identifying protein modulators (e.g., antibody agonists) of eukaryotic cells. The methods typically involve expressing a combinatorial agent library (e.g., via lentiviral vectors) inside a eukaryotic cell type (e.g., a mammalian cell) and then directly selecting for agents (e.g., antibodies) that are agonist of a target molecule (e.g., a signaling receptor) that modulates a phenotype of or elicits a cellular response in the cell. Some related methods involve co-culturing a cell expressing a combinatorial agent library and a second cell, and then selecting agents that modulate a phenotype of or elicit a cellular response in the second cell. Preferably, the agents are antibodies and are introduced into and expressed in the starting cells under conditions each individual cell expresses no more than 3 different members of the antibody library.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: December 3, 2019
    Assignee: The Scripps Research Institute
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20190177418
    Abstract: The invention provides TrkB agonist antibodies or antigen-binding fragments that specifically enhance TrkB signaling activities. The invention also provides therapeutic methods of using such antibodies for promoting survival and regeneration of retinal ganglion cells, and for treating or preventing subjects suffering from or at risk of developing various neurodegenerative conditions such as glaucoma.
    Type: Application
    Filed: May 2, 2017
    Publication date: June 13, 2019
    Inventors: Richard A. Lerner, Ronald M. Lindsay, Jia Xie
  • Publication number: 20190016774
    Abstract: The invention provides combinatorial peptide or polypeptide libraries that can become membrane tethered once expressed in cells. The invention additionally provides methods for selecting peptide modulators (e.g., agonists) of GPCRs from the combinatorial libraries of the invention. The invention also provides novel GPCR polypeptide modulators, e.g., biased polypeptide agonists of the glucagon-like peptide 1 receptor (GLP-1R). The invention further provides methods of promoting insulin sensitivity, lowering blood glucose, and reducing body weight as well as methods for treating various diseases such as diabetes and obesity.
    Type: Application
    Filed: April 1, 2016
    Publication date: January 17, 2019
    Inventors: Richard A. LERNER, Hongkai ZHANG, Patricia MC DONALD, Jia XIE, Emmanuel STURCHLER
  • Publication number: 20180298051
    Abstract: The present invention provides methods for generating functional derivatives of effector polypeptides (e.g., hormones and receptor ligands) embedded in a different protein scaffold (e.g., antibody scaffolds). The methods involve modifying the effector polypeptide with a combinatorial library of terminal linker sequences, inserting the modified sequences into the host scaffold, and then selecting functional derivatives from the library of modified polypeptide sequences embedded in the host scaffold. As exemplifications, the invention also provides specific functional derivatives of leptin, scFSH and scRelaxin embedded in an antibody scaffold, as well as therapeutic applications of such functional fusion molecules.
    Type: Application
    Filed: December 1, 2015
    Publication date: October 18, 2018
    Inventors: Yingjie Peng, Richard A. Lerner, Ronald M. Lindsay
  • Publication number: 20180119133
    Abstract: The invention provides methods for identifying binding partners (e.g., peptide ligands) that binds to a target protein (e.g., a cellular receptor). The methods entail co-localized expression of the target protein and candidate binding partners, and selection of binding partners based on their proximity in the plasma membrane.
    Type: Application
    Filed: October 16, 2015
    Publication date: May 3, 2018
    Inventors: Richard A. Lerner, Hongkai Zhang, Jia Xie
  • Publication number: 20180002425
    Abstract: The invention provides methods for identifying protein modulators (e.g., antibody agonists) of eukaryotic cells. The methods typically involve expressing a combinatorial agent library (e.g., via lentiviral vectors) inside a eukaryotic cell type (e.g., a mammalian cell) and then directly selecting for agents (e.g., antibodies) that are agonist of a target molecule (e.g., a signaling receptor) that modulates a phenotype of or elicits a cellular response in the cell. Some related methods involve co-culturing a cell expressing a combinatorial agent library and a second cell, and then selecting agents that modulate a phenotype of or elicit a cellular response in the second cell. Preferably, the agents are antibodies and are introduced into and expressed in the starting cells under conditions each individual cell expresses no more than 3 different members of the antibody library.
    Type: Application
    Filed: August 8, 2017
    Publication date: January 4, 2018
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20170320921
    Abstract: The invention relates to a group of isolated polypeptides and derivatives that can bind genetically to immunoglobulins or antibodies. The invention also relates to industrial and other applications of these molecules, e.g., antibody purifications.
    Type: Application
    Filed: February 2, 2015
    Publication date: November 9, 2017
    Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
  • Patent number: 9738719
    Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: August 22, 2017
    Assignee: The Scripps Research Institute
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Patent number: 9593150
    Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: March 14, 2017
    Assignee: The Scripps Research Institute
    Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
  • Publication number: 20150316561
    Abstract: Methods for Identifying protein modulators of eukaryotic cells by expressing a combinatorial library of potential agonists inside a eukaryotic cell and then directly selecting for an agonist of a target molecule. Some methods involve co-culturing a cell expressing a combinatorial library of potential agonists and a second cell, and then selecting agents that modulate a phenotype of or a desired cellular response in the second cell. Preferably, the agonists are antibodies introduced into and expressed in the starting cells, such as agonist anti-EpoR, anti-TpoR, or G-CSFR antibodies. Also disclosed are methods for selecting from combinatorial antibody libraries bispecific antibodies that can regulate cell phenotypes.
    Type: Application
    Filed: August 16, 2013
    Publication date: November 5, 2015
    Inventors: Hongkai Zhang, Ian A. Wilson, Richard A. Lerner
  • Publication number: 20150246953
    Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.
    Type: Application
    Filed: July 16, 2013
    Publication date: September 3, 2015
    Inventors: Rajesh Grover, Richard Lerner, Ian Wilson, Xueyong Zhu
  • Publication number: 20150079172
    Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D2 receptor signaling systems.
    Type: Application
    Filed: April 14, 2013
    Publication date: March 19, 2015
    Inventors: Sharon Mates, Robert Davis, Peng Li, Lawrence Wennogle, Richard A. Lerner
  • Patent number: 8338107
    Abstract: The present invention relates to a method for isolating from the immunological gene repertoire a gene coding for a receptor having the ability to bind a preselected ligand. Receptors produced by the gene isolated by the method, particularly catalytic receptors, are also contemplated.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: December 25, 2012
    Assignees: Scripps Research Institute, Medical Research Institute, Catalyst Assets LLC
    Inventors: William D. Huse, Gregory P. Winter, Lutz Riechmann, Joseph A. Sorge, Richard A. Lerner